|By PR Newswire||
|September 28, 2012 11:44 AM EDT||
NEW YORK, Sept. 28, 2012 /PRNewswire/ -- Chandler Chicco Companies (CCC), a global health communications group and part of inVentiv Health, Inc., was named Global Healthcare Agency of the Year by The Holmes Report, an online publication which reports public relations industry news, trends and analysis. The report attributes Chandler Chicco Companies' ability to quickly identify the issues impacting its clients' business and its suite of services as reasons for the honor.
Chandler Chicco Companies was recognized by The Holmes Report for its accomplishments and strategy in the past year, specifically noting that "the firm's diversification has paid dividends in terms of its performance." The report also lauded CCC for quickly identifying client challenges in the marketplace and offering integrated solutions, such as specialties focused on market access, digital and social media, and consumer health and wellness.
"Being named Global Healthcare Agency of the Year by The Holmes Report is a tremendous honor," said Bob Chandler president and CEO of Chandler Chicco Companies. "We are deeply committed to providing our clients with unmatched insights to help navigate the complex and ever-changing health environment. Our entire organization is incredibly passionate about what we do, which makes this recognition so rewarding."
In the past year, CCC has expanded its footprint globally with offices now in Germany and China. The organization has more than 400 people worldwide with deep expertise in a variety of disciplines critical to success for healthcare companies. Chandler Chicco Companies was previously recognized by The Holmes Report as Healthcare Agency of the Decade from 2000-2010 for its growth and prosperity as a specialist agency and as a benchmark for quality in healthcare communications.
About Chandler Chicco Companies
Chandler Chicco Companies (CCC) is a global health communications group that delivers unmatched perspective and creative know-how. With an integrated approach to communications, CCC offers best-in-class capabilities spanning public relations, digital and social media, medical and scientific education, marketing and branding, graphic design and multimedia, event production and research and measurement. Companies under the Chandler Chicco umbrella include: Allidura Consumer, Brandtectonics, Biosector 2, Chamberlain Healthcare Public Relations, Chandler Chicco Agency, Chandler Chicco Digital, Chandler Chicco Productions, Determinus, Haas & Health Partner Public Relations, Ingenda Communications, Litmus Medical Marketing & Education, 'nition Design, SanCom Creative Communication Solutions (CCS), and SharedVoice PR.
CCC is part of inVentiv Health, Inc., with companies based in New York, Los Angeles, Washington, London, Paris, Shanghai and Eltville (Frankfurt), as well as global healthcare network operations in 40 markets. For more information, visit www.chandlerchiccocompanies.com.
About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv's client roster includes more than 550 pharmaceutical, biotech and life sciences companies. With 13,000 employees in 40 countries, inVentiv rapidly transforms promising ideas into commercial reality. inVentiv Health is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit www.inventivhealth.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of the consummation of any announced and future acquisitions; the impact of any additional leverage we may incur in connection with the financing of acquisitions, on our ratings and the ratings of our debt securities; our ability to sufficiently increase our revenues and maintain or decrease expenses and cash capital expenditures to permit us to fund our operations; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers from future healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and the resulting synergies; the resolution of purchase price adjustment disputes in connection with our recent acquisitions and related impacts; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully implement from a timing and cost perspective any changes in applicable laws; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that client agreements will be terminated or not renewed; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; the impact of customer project delays and cancellations; our ability to convert backlog into revenue; the potential liability associated with bringing new drugs to market, including potential liability from injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memorandums provided in connection with the issuance of our senior secured notes for further discussion of these risks and other factors.
SOURCE Chandler Chicco Companies